CymaBay Therapeutics Inc
Buy, Hold or Sell?
Should you buy, hold or sell Cymabay?
I guess you are interested in CymaBay Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.
Let's analyse Cymabay
Let's start. I'm going to help you getting a better view of CymaBay Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.
Show more...
- Company's Financial Health
A deep dive into the books. How are the numbers doing? Is CymaBay Therapeutics Inc even making a profit? Is the company skyrocketing? Or is it sinking like the Titanic. The trend is your friend. - Market Valuation
Finally, you now have an insight of how CymaBay Therapeutics Inc is doing in the market. If the company is worth buying. The latest step is to find out how other investors value CymaBay Therapeutics Inc. The closing price on 2023-02-03 was €7.6 per share. Is the company over- or underpriced? - Key Performance Indicators
A total overlook on how the company is doing. Based on the (trends in) the key performance indicators.
1. Valuation of Cymabay
€7.60
€0.66
2. Growth of Cymabay
Is Cymabay growing?
Current year | Previous year | Grow | Grow % | |
---|---|---|---|---|
How rich? | $60.1m | $116.1m | -$20.3m | -21.3% |
How much money is Cymabay making?
Current year | Previous year | Grow | Grow % | |
---|---|---|---|---|
Making money | -$26.4m | -$19.7m | -$6.6m | -25.2% |
Net Profit Margin | 0.0% | 0.0% | - | - |
How much money comes from the company's main activities?
3. Financial Health of Cymabay
Comparing to competitors in the Biotechnology industry
Industry Rankings (Biotechnology)
Summary
Financial Health
Compared to previous year | Compared to industry | |
---|---|---|
Using its assets, the company is very inefficient in making profit. | ||
Using its investors money, the company is very inefficient in making profit. |
Compared to previous year | Compared to industry |
---|
Compared to previous year | Compared to industry | |
---|---|---|
The company is very able to pay all its short-term debts. | ||
The company is very able to pay all its short-term debts with the most liquid assets. |
Compared to previous year | Compared to industry | |
---|---|---|
The company is very able to pay all its debts by selling its assets. | ||
The company is able to pay all its debts with equity. |
1.1. Profitability of CymaBay Therapeutics Inc.
1.1. Profitability
1.1.1. Net Profit Margin
- Above 10% is considered healthy but always compare Cymabay to the Biotechnology industry mean.
- A Net Profit Margin of 0.0% means that €0.00 for each €1 in revenue is generated as profit.
Let's take a look of the Net Profit Margin trends of CymaBay Therapeutics Inc:
- The MRQ is 0.0%. The data is not here.
Trends
Compared to industry (Biotechnology)
Let compare the company's Net Profit Margin with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is -223.6%. trending up. +2
- The TTM average (mean) in the Biotechnology industry is -281.7%. trending up. +2
1.1.2. Return on Assets
- Above 5% is considered healthy but always compare Cymabay to the Biotechnology industry mean.
- -15.4% Return on Assets means that Cymabay generated €-0.15 profit for each $1 in assets.
Let's take a look of the Return on Assets trends of CymaBay Therapeutics Inc:
Trends
- The YOY is -15.3%. Compared to the TTM, the mid term is trending up. +2
- The 5Y is -12.6%. Compared to the TTM, the 5Y term is trending down. -2
- The 10Y is -12.6%. Compared to the 5Y term, the 10Y term is not trending.
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
MRQ | -15.4% | TTM | -14.4% | -1.0% | |
TTM | -14.4% | YOY | -15.3% | +0.9% | |
TTM | -14.4% | 5Y | -12.6% | -1.8% | |
5Y | -12.6% | 10Y | -12.6% | 0.0% |
Compared to industry (Biotechnology)
Let compare the company's Return on Assets with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is -9.9%. trending down. -2
- The TTM average (mean) in the Biotechnology industry is -8.9%. trending down. -2
1.1.3. Return on Equity
- Above 15%-20% is considered healthy but always compare Cymabay to the Biotechnology industry mean.
- -40.7% Return on Equity means Cymabay generated €-0.41 for each €1 the owners (shareholders) invested.
Let's take a look of the Return on Equity trends of CymaBay Therapeutics Inc:
Trends
- The YOY is -18.1%. Compared to the TTM, the mid term is trending down. -2
- The 5Y is -18.6%. Compared to the TTM, the 5Y term is trending down. -2
- The 10Y is -18.6%. Compared to the 5Y term, the 10Y term is not trending.
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
MRQ | -40.7% | TTM | -29.9% | -10.9% | |
TTM | -29.9% | YOY | -18.1% | -11.7% | |
TTM | -29.9% | 5Y | -18.6% | -11.3% | |
5Y | -18.6% | 10Y | -18.6% | 0.0% |
Compared to industry (Biotechnology)
Let compare the company's Return on Equity with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is -12.0%. trending down. -2
- The TTM average (mean) in the Biotechnology industry is -11.5%. trending down. -2
1.2. Operating Efficiency of CymaBay Therapeutics Inc.
1.2. Operating Efficiency
1.2.1. Operating Margin
- Measures how much profit Cymabay makes for each €1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
- Above 15% is considered healthy but always compare Cymabay to the Biotechnology industry mean.
- An Operating Margin of 0.0% means the company generated €0.00 for each €1 in revenue (before taxes).
Let's take a look of the Operating Margin trends of CymaBay Therapeutics Inc:
- The MRQ is 0.0%. The data is not here.
Trends
Compared to industry (Biotechnology)
Let compare the company's Operating Margin with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is -207.3%. trending up. +2
- The TTM average (mean) in the Biotechnology industry is -271.0%. trending up. +2
1.2.2. Operating Ratio
- Below 1 is considered healthy (always compare to Biotechnology industry mean).
- An Operation Ratio of 0.00 means that the operating costs are €0.00 for each €1 in net sales.
Let's take a look of the Operating Ratio trends of CymaBay Therapeutics Inc:
- The MRQ is 0.000. The data is not here.
Trends
Compared to industry (Biotechnology)
Let compare the company's Operating Ratio with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is 2.871. trending down. +2
- The TTM average (mean) in the Biotechnology industry is 3.504. trending down. +2
1.3. Liquidity of CymaBay Therapeutics Inc.
1.3. Liquidity
1.3.1. Current Ratio
- Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
- A Current Ratio of 12.20 means the company has €12.20 in assets for each €1 in short-term debts.
Let's take a look of the Current Ratio trends of CymaBay Therapeutics Inc:
Trends
- The YOY is 13.779. Compared to the TTM, the mid term is trending down. -2
- The 5Y is 13.780. Compared to the TTM, the 5Y term is trending down. -2
- The 10Y is 13.780. Compared to the 5Y term, the 10Y term is not trending.
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
MRQ | 12.204 | TTM | 12.388 | -0.184 | |
TTM | 12.388 | YOY | 13.779 | -1.391 | |
TTM | 12.388 | 5Y | 13.780 | -1.392 | |
5Y | 13.780 | 10Y | 13.780 | 0.000 |
Compared to industry (Biotechnology)
Let compare the company's Current Ratio with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is 5.117. trending up. +2
- The TTM average (mean) in the Biotechnology industry is 5.755. trending up. +2
1.3.2. Quick Ratio
- Above 1 is considered healthy but always compare Cymabay to the Biotechnology industry mean.
- A Quick Ratio of 9.65 means the company can pay off €9.65 for each €1 in debt (using most liquid assets).
Let's take a look of the Quick Ratio trends of CymaBay Therapeutics Inc:
Trends
- The YOY is 8.614. Compared to the TTM, the mid term is trending down. -2
- The 5Y is 8.668. Compared to the TTM, the 5Y term is trending down. -2
- The 10Y is 8.668. Compared to the 5Y term, the 10Y term is not trending.
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
MRQ | 9.655 | TTM | 7.492 | +2.162 | |
TTM | 7.492 | YOY | 8.614 | -1.121 | |
TTM | 7.492 | 5Y | 8.668 | -1.175 | |
5Y | 8.668 | 10Y | 8.668 | 0.000 |
Compared to industry (Biotechnology)
Let compare the company's Quick Ratio with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is 4.284. trending up. +2
- The TTM average (mean) in the Biotechnology industry is 4.664. trending up. +2
1.4. Solvency of CymaBay Therapeutics Inc.
1.3. Liquidity
1.4.1. Debt to Asset Ratio
- Below 1 (100%) is considered healthy but always compare Cymabay to Biotechnology industry mean.
- A Debt to Asset Ratio of 0.62 means that Cymabay assets are financed with 62.2% credit (debt) and the remaining percentage (100% - 62.2%) is financed by its owners/shareholders.
Let's take a look of the Debt to Asset Ratio trends of CymaBay Therapeutics Inc:
Trends
- The YOY is 0.129. Compared to the TTM, the mid term is trending up. -2
- The 5Y is 0.220. Compared to the TTM, the 5Y term is trending up. -2
- The 10Y is 0.220. Compared to the 5Y term, the 10Y term is not trending.
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
MRQ | 0.622 | TTM | 0.491 | +0.131 | |
TTM | 0.491 | YOY | 0.129 | +0.363 | |
TTM | 0.491 | 5Y | 0.220 | +0.271 | |
5Y | 0.220 | 10Y | 0.220 | 0.000 |
Compared to industry (Biotechnology)
Let compare the company's Debt to Asset Ratio with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is 0.278. trending up. -2
- The TTM average (mean) in the Biotechnology industry is 0.277. trending up. -2
1.4.2. Debt to Equity Ratio
- Below 2 is considered healthy but always compare Cymabay to the Biotechnology industry mean.
- A Debt to Equity ratio of 164.6% means that company has €1.65 debt for each €1 in shareholders equity.
Let's take a look of the Debt to Equity Ratio trends of CymaBay Therapeutics Inc:
Trends
- The YOY is 0.163. Compared to the TTM, the mid term is trending up. -2
- The 5Y is 0.405. Compared to the TTM, the 5Y term is trending up. -2
- The 10Y is 0.405. Compared to the 5Y term, the 10Y term is not trending.
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
MRQ | 1.646 | TTM | 1.048 | +0.598 | |
TTM | 1.048 | YOY | 0.163 | +0.885 | |
TTM | 1.048 | 5Y | 0.405 | +0.643 | |
5Y | 0.405 | 10Y | 0.405 | 0.000 |
Compared to industry (Biotechnology)
Let compare the company's Debt to Equity Ratio with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is 0.315. trending up. -2
- The TTM average (mean) in the Biotechnology industry is 0.317. trending up. -2
2. Market Valuation of CymaBay Therapeutics Inc
2. Earnings Per Share
2.1. Price to Earnings Ratio
- Above 15 is considered overpriced but always compare Cymabay to the Biotechnology industry mean.
- A PE ratio of -13.13 means the investor is paying €-13.13 for every €1 in earnings.
Let's take a look of the Price to Earnings Ratio trends of CymaBay Therapeutics Inc:
Trends
- The YOY is -18.089. Compared to the TTM, the mid term is trending up. -2
- The 5Y is -16.820. Compared to the TTM, the 5Y term is trending up. -2
- The 10Y is -16.820. Compared to the 5Y term, the 10Y term is not trending.
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
EOD | -28.347 | MRQ | -13.129 | -15.218 | |
MRQ | -13.129 | TTM | -10.239 | -2.890 | |
TTM | -10.239 | YOY | -18.089 | +7.850 | |
TTM | -10.239 | 5Y | -16.820 | +6.581 | |
5Y | -16.820 | 10Y | -16.820 | 0.000 |
Compared to industry (Biotechnology)
Let compare the company's Price to Earnings Ratio with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is -9.792. trending down. +2
- The TTM average (mean) in the Biotechnology industry is -16.243. trending up. -2
2.2. Price Earnings to Growth Ratio
- Lower is better.
- A PEG ratio of 1 means the market price of the stock and the expected future earnings are on par.
Let's take a look of the Price Earnings to Growth Ratio trends of CymaBay Therapeutics Inc:
Trends
- The YOY is -24.410. Compared to the TTM, the mid term is trending up. -2
- The 5Y is -18.778. Compared to the TTM, the 5Y term is trending up. -2
- The 10Y is -18.778. Compared to the 5Y term, the 10Y term is not trending.
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
MRQ | -11.984 | TTM | -10.496 | -1.488 | |
TTM | -10.496 | YOY | -24.410 | +13.914 | |
TTM | -10.496 | 5Y | -18.778 | +8.282 | |
5Y | -18.778 | 10Y | -18.778 | 0.000 |
Compared to industry (Biotechnology)
Let compare the company's Price Earnings to Growth Ratio with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is -0.032. trending down. +2
- The TTM average (mean) in the Biotechnology industry is 0.004. trending down. +2
2. Book Value per Share
2.3. Price to Book Ratio
- At or below 1 is considered healthy (always compare to Biotechnology industry mean).
- A PB ratio of 5.35 means the investor is paying €5.35 for each €1 in book value.
Let's take a look of the Price to Book Ratio trends of CymaBay Therapeutics Inc:
Trends
- The YOY is 2.972. Compared to the TTM, the mid term is trending up. -2
- The 5Y is 2.559. Compared to the TTM, the 5Y term is trending up. -2
- The 10Y is 2.559. Compared to the 5Y term, the 10Y term is not trending.
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
EOD | 11.543 | MRQ | 5.346 | +6.197 | |
MRQ | 5.346 | TTM | 3.156 | +2.190 | |
TTM | 3.156 | YOY | 2.972 | +0.185 | |
TTM | 3.156 | 5Y | 2.559 | +0.597 | |
5Y | 2.559 | 10Y | 2.559 | 0.000 |
Compared to industry (Biotechnology)
Let compare the company's Price to Book Ratio with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is 2.006. trending up. -2
- The TTM average (mean) in the Biotechnology industry is 2.774. trending up. -2
2. Total Gains per Share
2.4. Latest News of CymaBay Therapeutics Inc
Does CymaBay Therapeutics Inc still have the same value as the quarterly reports suggest? Recent changes may be an indication that the value of the company is changing. Read the news from CymaBay Therapeutics Inc to keep up to date. Note: the news is often already included in the price.
Date | Title | Read |
---|---|---|
2023-01-17 14:50 | Here's What Could Help CymaBay Therapeutics Inc. (CBAY) Maintain Its Recent Price Strength | Read |
3. Summary
3.1. Key Performance Indicators
The key performance indicators of CymaBay Therapeutics Inc compared to the Most Recent Quarter (MRQ).
End of day | +/- | Most Recent Quarter | Trailing 12 Months | +/- | Year-Over-Year | +/- | 5 Year | +/- | 10 Year | +/- | |
---|---|---|---|---|---|---|---|---|---|---|---|
Book Value Change Per Share | - | - | -0.244 | -0.074 | -70% | -0.190 | -22% | 0.051 | -581% | 0.051 | -581% |
Book Value Growth | - | - | 0.730 | 0.958 | -24% | 0.864 | -16% | 0.916 | -20% | 0.916 | -20% |
Book Value Per Share | - | - | 0.658 | 1.047 | -37% | 1.271 | -48% | 1.468 | -55% | 1.468 | -55% |
Book Value Per Share Growth | - | - | 0.730 | 0.958 | -24% | 0.864 | -16% | 0.916 | -20% | 0.916 | -20% |
Current Ratio | - | - | 12.204 | 12.388 | -1% | 13.779 | -11% | 13.780 | -11% | 13.780 | -11% |
Debt To Asset Ratio | - | - | 0.622 | 0.491 | +27% | 0.129 | +383% | 0.220 | +183% | 0.220 | +183% |
Debt To Equity Ratio | - | - | 1.646 | 1.048 | +57% | 0.163 | +908% | 0.405 | +307% | 0.405 | +307% |
Dividend Per Share | - | - | - | - | 0% | - | 0% | - | 0% | - | 0% |
Eps | - | - | -0.268 | -0.290 | +8% | -0.217 | -19% | -0.232 | -13% | -0.232 | -13% |
Eps Growth | - | - | 1.096 | 0.976 | +12% | 0.802 | +37% | 0.972 | +13% | 0.972 | +13% |
Free Cash Flow Per Share | - | - | -0.192 | -0.218 | +14% | -0.192 | 0% | -0.194 | +1% | -0.194 | +1% |
Free Cash Flow Per Share Growth | - | - | 1.223 | 0.907 | +35% | 0.723 | +69% | 0.941 | +30% | 0.941 | +30% |
Free Cash Flow To Equity Per Share | - | - | -0.192 | 0.109 | -275% | -0.127 | -34% | -0.074 | -62% | -0.074 | -62% |
Free Cash Flow To Equity Per Share Growth | - | - | 1.223 | -3.462 | +383% | 1.022 | +20% | -0.414 | +134% | -0.414 | +134% |
Gross Profit Margin | - | - | 1.000 | 1.000 | 0% | 1.000 | 0% | 1.000 | 0% | 1.000 | 0% |
Intrinsic Value_10Y_max | - | - | -2.415 | - | - | - | - | - | - | - | - |
Intrinsic Value_10Y_min | - | - | -9.275 | - | - | - | - | - | - | - | - |
Intrinsic Value_1Y_max | - | - | -0.684 | - | - | - | - | - | - | - | - |
Intrinsic Value_1Y_min | - | - | -0.887 | - | - | - | - | - | - | - | - |
Intrinsic Value_3Y_max | - | - | -1.719 | - | - | - | - | - | - | - | - |
Intrinsic Value_3Y_min | - | - | -2.719 | - | - | - | - | - | - | - | - |
Intrinsic Value_5Y_max | - | - | -2.348 | - | - | - | - | - | - | - | - |
Intrinsic Value_5Y_min | - | - | -4.593 | - | - | - | - | - | - | - | - |
Net Profit Margin | - | - | - | - | 0% | - | 0% | - | 0% | - | 0% |
Operating Margin | - | - | - | - | 0% | - | 0% | - | 0% | - | 0% |
Operating Ratio | - | - | - | - | 0% | - | 0% | - | 0% | - | 0% |
Pb Ratio | 11.543 | +54% | 5.346 | 3.156 | +69% | 2.972 | +80% | 2.559 | +109% | 2.559 | +109% |
Pe Ratio | -28.347 | -116% | -13.129 | -10.239 | -22% | -18.089 | +38% | -16.820 | +28% | -16.820 | +28% |
Peg Ratio | - | - | -11.984 | -10.496 | -12% | -24.410 | +104% | -18.778 | +57% | -18.778 | +57% |
Price Per Share | 7.600 | +54% | 3.520 | 2.945 | +20% | 3.739 | -6% | 3.350 | +5% | 3.350 | +5% |
Price To Total Gains Ratio | -31.179 | -116% | -14.441 | -7.223 | -50% | -20.621 | +43% | -16.715 | +16% | -16.715 | +16% |
Profit Growth | - | - | 1.096 | 0.976 | +12% | 0.802 | +37% | 0.972 | +13% | 0.972 | +13% |
Quick Ratio | - | - | 9.655 | 7.492 | +29% | 8.614 | +12% | 8.668 | +11% | 8.668 | +11% |
Return On Assets | - | - | -0.154 | -0.144 | -6% | -0.153 | 0% | -0.126 | -18% | -0.126 | -18% |
Return On Equity | - | - | -0.407 | -0.299 | -27% | -0.181 | -55% | -0.186 | -54% | -0.186 | -54% |
Total Gains Per Share | - | - | -0.244 | -0.074 | -70% | -0.190 | -22% | 0.051 | -581% | 0.051 | -581% |
Total Gains Per Share Growth | - | - | 1.106 | 1.466 | -25% | 0.757 | +46% | 1.046 | +6% | 1.046 | +6% |
Usd Book Value | - | - | 60165130.935 | 95717776.375 | -37% | 116101166.455 | -48% | 134101085.580 | -55% | 134101085.580 | -55% |
Usd Book Value Change Per Share | - | - | -0.263 | -0.079 | -70% | -0.205 | -22% | 0.055 | -581% | 0.055 | -581% |
Usd Book Value Per Share | - | - | 0.710 | 1.130 | -37% | 1.371 | -48% | 1.584 | -55% | 1.584 | -55% |
Usd Dividend Per Share | - | - | - | - | 0% | - | 0% | - | 0% | - | 0% |
Usd Eps | - | - | -0.289 | -0.313 | +8% | -0.234 | -19% | -0.251 | -13% | -0.251 | -13% |
Usd Free Cash Flow | - | - | -17529250.568 | -19921238.932 | +14% | -17519002.760 | 0% | -13821889.710 | -21% | -13821889.710 | -21% |
Usd Free Cash Flow Per Share | - | - | -0.207 | -0.235 | +14% | -0.207 | 0% | -0.210 | +1% | -0.210 | +1% |
Usd Free Cash Flow To Equity Per Share | - | - | -0.207 | 0.118 | -275% | -0.138 | -34% | -0.079 | -62% | -0.079 | -62% |
Usd Price Per Share | 8.201 | +54% | 3.798 | 3.178 | +20% | 4.035 | -6% | 3.615 | +5% | 3.615 | +5% |
Usd Profit | - | - | -24499759.606 | -26472087.733 | +8% | -19797265.449 | -19% | -21229843.642 | -13% | -21229843.642 | -13% |
Usd Revenue | - | - | - | - | 0% | - | 0% | - | 0% | - | 0% |
Usd Total Gains Per Share | - | - | -0.263 | -0.079 | -70% | -0.205 | -22% | 0.055 | -581% | 0.055 | -581% |
EOD | +2 -3 | MRQ | TTM | +14 -20 | YOY | +8 -26 | 5Y | +10 -24 | 10Y | +10 -24 |
3.2. Fundamental Score
Penke's Stock Scanner
Indicator | Condition | Value | ||
---|---|---|---|---|
Price to Earnings Ratio (EOD) | Between | 0-15 | -28.347 | |
Price to Book Ratio (EOD) | Between | 0-1 | 11.543 | |
Net Profit Margin (MRQ) | Greater than | 0 | 0.000 | |
Operating Margin (MRQ) | Greater than | 0 | 0.000 | |
Quick Ratio (MRQ) | Greater than | 1 | 9.655 | |
Current Ratio (MRQ) | Greater than | 1 | 12.204 | |
Debt to Asset Ratio (MRQ) | Less than | 1 | 0.622 | |
Debt to Equity Ratio (MRQ) | Less than | 1 | 1.646 | |
Return on Equity (MRQ) | Greater than | 0.15 | -0.407 | |
Return on Assets (MRQ) | Greater than | 0.05 | -0.154 | |
Total | 3/10 (30.0%) |
3.3. Technical Score
Penke's Symbol Scanner
Indicator | Condition | Value | ||
---|---|---|---|---|
Rsi | Greater than | 50 | 75.349 | |
Ma 20 | Greater than | Ma 50 | 6.390 | |
Ma 50 | Greater than | Ma 100 | 5.145 | |
Ma 100 | Greater than | Ma 200 | 4.280 | |
Open | Greater than | Close | 7.600 | |
Total | 4/5 (80.0%) |
Latest Balance Sheet
Balance Sheet of 2022-09-30. Currency in USD. All numbers in thousands.
Summary
As reported | |
---|---|
Total Liabilities | 99,069 |
Total Stockholder Equity | + 60,178 |
Total Assets | = 159,247 |
Assets
Total Current Assets
Long-term Assets
Property Plant Equipment | 1,042 |
Other Assets | 3,081 |
Long-term Assets (as reported) | 4,123 |
---|---|
Long-term Assets (calculated) | 4,123 |
+/- | 0 |
Liabilities & Shareholders' Equity
Total Current Liabilities
Long-term Liabilities
Long term Debt | 86,152 |
Capital Lease Obligations Min Short Term Debt | 845 |
Long-term Liabilities (as reported) | 86,358 |
---|---|
Long-term Liabilities (calculated) | 86,997 |
+/- | 639 |
Total Stockholder Equity
Common Stock | 8 |
Other Stockholders Equity | -574 |
Total Stockholder Equity (as reported) | 60,178 |
---|---|
Total Stockholder Equity (calculated) | -566 |
+/- | 60,744 |
Other
Capital Stock | 8 |
Common Stock Shares Outstanding | 84,678 |
Net Debt | 55,461 |
Net Invested Capital | 146,330 |
Net Tangible Assets | 60,178 |
Net Working Capital | 142,413 |
Balance Sheet
Currency in USD. All numbers in thousands.
Trend | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
> Total Assets |
| 159,247 | 177,724 | 200,642 | 202,318 | 122,902 | 117,041 | 136,682 | 153,825 | 168,486 | 176,597 | 188,600 | 205,727 | 231,800 | |||||||||||||
> Total Current Assets |
| 155,124 | 166,611 | 192,046 | 191,099 | 119,576 | 113,813 | 133,273 | 151,585 | 166,129 | 174,102 | 185,949 | 202,923 | 227,771 | |||||||||||||
Cash And Cash Equivalents |
| 30,691 | 52,753 | 73,995 | 125,806 | 68,963 | 32,897 | 43,326 | 28,193 | 47,273 | 96,051 | 56,794 | 24,869 | 43,462 | |||||||||||||
Short-term Investments |
| 122,724 | 111,130 | 114,564 | 60,729 | 44,825 | 73,237 | 82,132 | 118,130 | 113,991 | 72,856 | 119,438 | 166,076 | 175,132 | |||||||||||||
Net Receivables |
| 0 | 0 | 0 | 0 | 69 | 227 | 265 | 277 | 284 | 209 | 377 | 687 | 509 | |||||||||||||
Other Current Assets |
| 668 | 1,103 | 1,384 | 2,371 | 5,071 | 6,060 | 5,631 | 2,221 | 3,761 | 4,012 | 7,922 | 9,910 | 7,900 | |||||||||||||
> Long-term Assets |
| 4,123 | 11,113 | 8,596 | 11,219 | 3,326 | 3,228 | 3,409 | 2,240 | 2,357 | 2,495 | 2,651 | 2,804 | 4,029 | |||||||||||||
Property Plant Equipment |
| 1,042 | 1,213 | 1,263 | 1,432 | 1,605 | 1,781 | 1,963 | 2,033 | 2,197 | 2,335 | 2,491 | 2,644 | 2,768 | |||||||||||||
Long Term Investments |
| 0 | 6,874 | 4,885 | 8,067 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||||||||||
Other Assets |
| 3,081 | 3,026 | 2,448 | 1,720 | 1,721 | 1,447 | 1,446 | 207 | 160 | 160 | 160 | 160 | 1,261 | |||||||||||||
> Total Liabilities |
| 99,069 | 95,267 | 93,261 | 69,381 | 35,844 | 9,947 | 9,036 | 11,119 | 11,851 | 10,989 | 13,552 | 19,379 | 19,209 | |||||||||||||
> Total Current Liabilities |
| 12,711 | 12,560 | 14,039 | 18,366 | 11,741 | 8,959 | 7,909 | 9,857 | 10,462 | 9,478 | 11,922 | 17,636 | 17,358 | |||||||||||||
Accounts payable |
| 479 | 866 | 199 | 2,728 | 764 | 1,050 | 1,606 | 231 | 947 | 476 | 1,213 | 2,503 | 1,494 | |||||||||||||
Other Current Liabilities |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 18 | 93 | 879 | 1,717 | 3,193 | 0 | |||||||||||||
> Long-term Liabilities |
| 86,358 | 82,707 | 79,222 | 51,015 | 24,103 | 988 | 1,127 | 1,262 | 1,389 | 1,511 | 1,630 | 1,743 | 1,851 | |||||||||||||
Capital Lease Obligations Min Short Term Debt |
| 845 | 988 | 1,127 | 1,262 | 1,389 | 1,511 | 1,629 | 1,744 | 1,851 | 1,954 | 2,054 | 2,150 | 2,240 | |||||||||||||
Other Liabilities |
| 0 | 0 | 0 | 0 | 23,259 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||||||||||
> Total Stockholder Equity |
| 60,178 | 82,457 | 107,381 | 132,937 | 87,058 | 107,094 | 127,646 | 142,706 | 156,635 | 165,608 | 175,048 | 186,348 | 212,591 | |||||||||||||
Common Stock |
| 8 | 8 | 8 | 8 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | |||||||||||||
Retained Earnings Total Equity | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||||||||||
Accumulated Other Comprehensive Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||||||||||
Capital Surplus | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||||||||||
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||||||||||
Other Stockholders Equity |
| -574 | -441 | -219 | -13 | -1 | 1 | -6 | 8 | 82 | 186 | -130 | 80 | 177 |
Balance Sheet
Currency in USD. All numbers in thousands.
Cash Flow
Currency in USD. All numbers in thousands.
Income Statement
Currency in USD. All numbers in thousands.
Latest Income Statement (annual, 2021-12-31)
Gross Profit (+$) | ||
---|---|---|
totalRevenue | 0 | |
Cost of Revenue | -- | |
Gross Profit | - | 0 |
Operating Income (+$) | ||
Gross Profit | - | |
Operating Expense | -87,582 | |
Operating Income | -87,582 | -87,582 |
Operating Expense (+$) | ||
Research Development | 64,542 | |
Selling General Administrative | 23,040 | |
Selling And Marketing Expenses | - | |
Operating Expense | 87,582 | 87,582 |
Net Interest Income (+$) | ||
Interest Income | 167 | |
Interest Expense | -2,583 | |
Net Interest Income | -2,416 | -2,416 |
Pretax Income (+$) | ||
Operating Income | -87,582 | |
Net Interest Income | -2,416 | |
Other Non-Operating Income Expenses | - | |
Income Before Tax (EBT) | -89,998 | -87,582 EBIT - interestExpense = -90,165 -89,998 -87,415 |
Interest Expense | 2,583 | |
Earnings Before Interest and Taxes (ebit) | -87,582 | -87,415 |
Earnings Before Interest and Taxes (ebitda) | -86,727 | |
After tax Income (+$) | ||
Income Before Tax | -89,998 | |
Tax Provision | -- | |
Net Income From Continuing Ops | -89,998 | -89,998 |
Net Income | -89,998 | |
Net Income Applicable To Common Shares | -89,998 | |
Non-recurring Events | ||
Discontinued Operations | - | |
Extraordinary Items | - | |
Effect of Accounting Charges | - | |
Other Items | - | |
Non Recurring | - | |
Other Operating Expenses | - | |
Total Other Income/Expenses Net | - | 2,416 |
Comments
Join the conversation.